The price of Rebif has increased four times faster than the rate of inflation, with Kay's insurer deciding to stop covering ...

"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

A biology teacher and mother-of-two has become the first UK patient to receive a "gamechanger" therapy to treat multiple ...

NEW YORK (Reuters Health) - Drugs used in the hope of slowing multiple sclerosis progression may help some patients, but at a very high cost, according to a study out Wednesday. The medications in ...

Women with multiple sclerosis (MS) are significantly less likely than men to be treated with disease-modifying therapies (DMTs) and highly effective DMTs (HE-DMTs), a new study showed. At comparable ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, according to new research. Photo by Adobe Stock/HealthDay News A person ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may repair damage caused by the condition. A study led by the University of ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study examined the ...

Specialty drugs, especially biologics, will constitute a significant portion of global drug spending by 2029, driven by cancer care costs. Autoimmune diseases and multiple sclerosis are key short-term ...